Certara, Inc.
A maker of biosimulation software that lets drug developers test medicines in virtual patients before real trials, Certara's tools include Simcyp, Phoenix, and Chemaxon, and are used by researchers and regulators around the world. It was formed in 2008 from the merger of Tripos and Pharsight, two pioneers in molecular modeling and clinical trial simulation. The coined name "Certara" echoes the word certainty — a nod to its aim of making drug development more predictable.
Granted 201.2K · Bought 24.1K
Granted 36.3K
Granted 113.4K
Granted 36.3K
Granted 24.1K · Sold 18.0K
Granted 113.4K · Sold 153.7K
Granted 143.7K
Granted 59.8K
Granted 36.3K
Granted 36.3K
Granted 36.3K
Granted 23.6K · Sold 24.8K
Granted 36.3K
Granted 56.5K
Granted 26.5K
Granted 14.8K
Granted 24.1K
Granted 10.8K
Granted 5.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Feehery William FCHIEF EXECUTIVE OFFICER, Director · 11 transactions | +9.4% | 2.36M | 201.2K | 24.1K | — |
| Cashman James E IIIDirector, Chairman · 3 transactions | +8.1% | 484.2K | 36.3K | — | — |
| Aspbury RobertPRESIDENT, PREDICTIVE TECH · 26 transactions | +16.5% | 321.7K | 113.4K | — | — |
| Walsh Matthew MDirector · 3 transactions | +20.5% | 213.3K | 36.3K | — | — |
| Traynor Richard M.SVP AND GENERAL COUNSEL · 11 transactions | +0.8% | 178.8Kas of Apr 2024 | 24.1K | — | 18.0K |
| Pedersen Leif EPRESIDENT, CHIEF COMMERCAL OFF · 26 transactions | -53.4% | 85.0K | 113.4K | — | 153.7K |
| Gallagher John EChief Financial Officer · 18 transactions | — | 62.1K | 143.7K | — | — |
| Resnick Jon MatthewChief Executive Officer, Director · 2 transactions | — | 59.8K | 59.8K | — | — |
| Collins CynthiaDirector · 3 transactions | +234.5% | 51.8K | 36.3K | — | — |
| Killefer NancyDirector · 3 transactions | +234.5% | 51.8K | 36.3K | — | — |
| Broshy EranDirector, Chairman · 3 transactions | +253.1% | 50.7K | 36.3K | — | — |
| Smith Patrick FPRESIDENT, DRUG DEV SOLUTIONS · 15 transactions | -16.5% | 50.1Kas of Oct 2024 | 23.6K | — | 24.8K |
| Crane Rosemary ADirector · 3 transactions | +389.8% | 45.7K | 36.3K | — | — |
| Corcoran DanielSVP and General Counsel · 10 transactions | — | 39.9K | 56.5K | — | — |
| Reynders John V WChief Financial Officer, Director · 2 transactions | — | 26.5K | 26.5K | — | — |
| Sherman Nicolette DCHIEF HUMAN RESOURCES OFFICER · 6 transactions | +77.3% | 25.7Kas of Apr 2024 | 14.8K | — | — |
| Anhalt RonaChief Human Resources Officer · 6 transactions | — | 19.0K | 24.1K | — | — |
| McKemey AdrianPresident, Drug Dev. Solutions · 2 transactions | — | 8.2K | 10.8K | — | — |
| Bedi ArjunDirector · 1 transaction | — | 5.5K | 5.5K | — | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 3 years: -172.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.